Skip to content

Bone Microcirculation After Extracorporeal Shock Wave Therapy

Effects of Extracorporeal Shock Wave Therapy in Bone Microcirculation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02424084
Enrollment
80
Registered
2015-04-22
Start date
2015-03-31
Completion date
2023-02-28
Last updated
2023-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fractured Metacarpal Bone, Fractured Scaphoid Bone, Intact Metacarpal Bone, Intact Scaphoid Bone

Brief summary

In trauma surgery and hand surgery treatment strategies of none healing bone fractures aim at replacing pseudarthrosis by well vascularized bone and improving microcirculation. Although previous studies indicate that extracorporeal shock wave therapy (ESWT) can accelerate bone healing in case of non-union, only a few studies focused on the elucidation of its mechanisms of action. Therefore, the aim of this study is to evaluate the microcirculatory effects of extracorporeal shock wave therapy on scaphoid bones and metacarpal and metatarsal in a human in-vivo setting for the first time.

Interventions

Extracorporeal Shock Wave Therapy

Sponsors

University Hospital Schleswig-Holstein
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid. * Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone. * Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid. * Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.

Exclusion criteria

* below 18 years of age * scar tissue above scaphoid or metacarpal bone * osteoporosis or comparable bone disease * medication that influences bones

Design outcomes

Primary

MeasureTime frameDescription
Change in microcirculation (composite outcome measure)Baseline and 1 minute post-dose* Bone blood flow \[arbitrary units AU\] * Bone blood velocity \[AU\] * Tissue oxygen saturation \[%\] * Relative postcapillary venous filling pressure \[AU\] (Composite outcome measure)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026